Achieve Life Sciences (ACHV, Financial) has revealed the comprehensive results from its second Phase 3 clinical trial, ORCA-3, published in the Journal of the American Medical Association Internal Medicine. This trial focused on evaluating the effectiveness of cytisinicline, a drug aimed at aiding smoking cessation, in 792 adult participants in the United States.
The study's authors reported that ORCA-3 validated earlier findings, demonstrating cytisinicline’s capability to aid in smoking cessation while being well-tolerated by users. By specifically targeting nicotine receptors, cytisinicline not only reduced nicotine cravings but also provided long-term cessation benefits observable at both 6-week and 12-week treatment durations, with extended effects noted up to 24 weeks.
These findings, consistent with results from the first Phase 3 trial, highlight cytisinicline's significant impact on quitting smoking, with study participants experiencing reduced nicotine cravings and decreased intake of nicotine. Notably, ORCA-3 participants had an average age of 53 years, smoked around 20 cigarettes daily at the outset, and most had attempted to quit four times previously, offering insights into its effectiveness for long-term smokers.
Achieve Life Sciences plans to advance its efforts by submitting a New Drug Application for cytisinicline to the U.S. Food and Drug Administration by June 2025, potentially bringing a novel smoking cessation treatment to market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Achieve Life Sciences Inc (ACHV, Financial) is $13.00 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 546.77% from the current price of $2.01. More detailed estimate data can be found on the Achieve Life Sciences Inc (ACHV) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Achieve Life Sciences Inc's (ACHV, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
